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OBJECTIVES: Arthritis is one of the most common chronic diseases among elderly. 
Approximately 50% of all elderly in the United States suffer from the disease. Drug
therapy plays an important role in decreasing morbidity and mortality associated with 
the disease. The objectives of this study are to evaluate the effect of prescription drug
insurance coverage on prescription drug use, and health among the elderly patients 
with arthritis. METHODS: Estimates are obtained using multivariate regression, and
a ﬁ xed-effect (within person) research design that controls for the unmeasured person-
speciﬁ c effects. Analyses were based on the Medicare Current Beneﬁ ciary Survey for
years 1992–2004. RESULTS: Estimates show that prescription drug coverage is associ-
ated with a 2%–15% increase in utilization of prescription drugs depending on the
type and generosity of the coverage. In addition, the effect of drug coverage on drug 
use differed depending on the type of drugs, and other co-morbid conditions. For
example, among arthritic patients, drug coverage increased use of diabetic drugs by
20%, whereas it had relatively low impact on use of cold medications (2%). We found 
no evidence that drug coverage improved hospitalization and general health status. 
CONCLUSIONS: Drug coverage plays a crucial role on the use of essential medica-
tions among elderly patients with arthritis. The results of the analysis also suggest the 
importance of controlling for selection bias. Our estimates on drug coverage were 
reduced markedly when we accounted for selection into plans.
PMS50
A PRELIMINARY ANALYSIS OF BIOLOGICS MEDICATION-TAKING
BEHAVIOR AMONG RHEUMATOID ARTHRITIS PATIENTS
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OBJECTIVES: Tumor necrosis factor blocker (TNFb) therapy is an expensive alterna-
tive for rheumatoid arthritis (RA) sufferers when other treatments have failed. The 
purpose of this analysis was to compare two products, adalimumab and etanercept, 
in terms of adherence, persistency, and appropriateness of use. METHODS: Retro-
spective claims data between October 2005-September 2008 were extracted from 
an organization with ^30,000 individuals. Inclusion criteria were primary diagnosis 
of RA, new start of TNFb therapy deﬁ ned as none in preceding sixmonths, and con-
tinuous enrollment at least 6 months pre- and 12 months post-TNFb initiation. A 
reﬁ ll grace period was deﬁ ned as ½ days supply for prescriptions 30 days or 1/3 
days supply for prescriptions 30days. RESULTS: A total of 334 individuals met 
criteria, and of those 57 received study medication; 12 were excluded for receiving
both medications during the 12-month period, leaving 43 individuals for analysis
(adalimumab n  24; etanercept n  19). No statistical differences (p  0.05) were 
found in adherence or persistency by drug, age, or gender. Mean medication possession
ratio (MPR) over 12 months was 0.61 (st dev  0.35) and mean annual days supply
was 228 (st dev  136). After the ﬁ rst month, 30% exceeded the reﬁ ll grace period,
and by month 6, this increased to 80%. Thirty-nine (91%) received other prescription 
RA medication in the 6 months prior to initiating TNFb therapy. CONCLUSIONS:
While preliminary, the results from this analysis indicate that gaps in adalimumab
and etanercept therapy occur early in care, thereby impacting adherence and persis-
tence rates. While individuals in this analysis received approximately seven total 
months of therapy over a year, gaps between reﬁ lls may impact effectiveness. Efforts 
to improve adherence and persistence of RA therapy are needed to maximize patient 
outcomes. Most patients had received alternative therapy before initiating TNFb
treatment, and none received concomitant TNFb therapy, which aligns with current 
guidelines.
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OBJECTIVES: To determine the mean induction and maintenance inﬂ iximab (IFX) 
dose per infusion and infusion patterns in patients with rheumatoid arthritis (RA)
enrolled in commercial health plans. METHODS: Medical/pharmacy claims (January
1, 2000 and December 31,2006) were obtained from a national commercial bench-
mark database. Inclusion criteria were patient age 18, q2 RA diagnosis codes,
no medical/pharmacy claims of biologic use during 6 months prior to IFX index
date (which occurred on or after ﬁ rst RA diagnosis date) and q365 days of IFX 
persistence. Patients were excluded if they had a diagnosis of ankylosing spondylitis,
psoriatic arthritis, psoriasis, Crohn’s disease, or ulcerative colitis. Infused doses 
were calculated by dividing the plan’s allowed amount per IFX claim (HCPCS code
J1745) by the acquisition cost for a 100 mg vial during the year of payment. Results 
were reported for induction (weeks 0–8), maintenance (weeks 9–52), and one-year 
time periods (weeks 0–52). Infusion patterns included the mean days between each
infusion during the ﬁ rst year of treatment. RESULTS: A total of 457 RA patients 
were identiﬁ ed (mean age  53 years; 74% female). A total of 425 evaluable patients 
with no missing infusion data were included in the dosing analysis. The mean IFX 
dose per infusion was 397, 455, and 437 mg for induction, maintenance, and one-year 
periods, respectively. A total of 98.5% of IFX-treated patients received a8 infusions 
during ﬁ rst year. Mean time between IFX infusions were as follows: 1st and 2nd  19 
days; 2nd and 3rd  29 days; 3rd and 4th  56 days; 4th and 5th  57 days; 5th 
and 6th  55 days; 6th and 7th  52 days; 7th and 8th  53 days. CONCLUSIONS:
This observational study reported IFX infusion patterns consistent with prescribing 
information which is useful for stakeholders’ understanding of real world IFX
utilization.
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OBJECTIVES: The aim of this study was to detect changes in non-steroidal anti-
inﬂ ammatory drugs (NSAIDs) ﬁ nancial expenditure and consumption according to 
the legal changes especially considering pricing policy (restrictive comparative pricing). 
Further, to analyze possible inﬂ uences of new studies (connection between NSAIDs 
and increased cardiovascular risks) on NSAIDs utilization. METHODS: The data was 
obtained from the Croatian National Health Insurance Institute and from pharma-
ceutical wholesalers for the seven-year period (2001–2007). Financial expenditure 
data are presented in Euros, while drug utilization data are presented in deﬁ ned daily
doses/1000 inhabitants/day (DDD/1000). RESULTS: In the investigated period the 
total expenditure of the group increased 10.39% while the related consumption of 
NSAID increased 1.95% (41.404 DDD/1000 to 42.224 DDD/1000). During the ﬁ rst 
part of the investigated period (from 2001–2005), before new pricing policy was 
introduced, the expenditure of NSAIDs increased 15.72% and the related consump-
tion 5.92%. After the new measures were introduced (2005), in the period from 
2005–2007 the ﬁ nancial expenditure of NSAIDs decreased 24.04% while usage 
decreased 4.03%. For the entire period diclofenac was the most frequently prescribed
NSAID, but its share in the total consumption of NSAIDs decreased from 54.33% in
2001 to 41.84% in 2007. CONCLUSIONS: The usage of NSAIDs in Croatia increased
during the investigated period, so in 2005 new pricing policy was introduced to slow 
down the ﬁ nancial expenditure. This resulted in a considerable ﬁ nancial decrease and 
the usage was almost on the same level. The decrease of diclofenac usage in 2007
could be explained as the result of the published studies (the end of 2006) concerning 
its cardiovascular side effects.
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OBJECTIVES: Determine if disparities in hip and knee replacement surgery exist
among osteoarthritis patients with Medicare supplement plan coverage (i.e., Medigap). 
METHODS: Data were obtained from UnitedHealth Group’s database of AARP
Medicare Medigap insureds. Patients were selected into the study if they had one or 
more medical claims with a diagnosis of osteoarthritis from July 1, 2006-June 30,
2007. Logistic regression analyses tested for age-, gender-, race-, or income-related 
differences in the likelihood of receiving a hip or knee replacement surgery. The regres-
sion models controlled for socioeconomics, health status, type of supplement plan,
and residential location. RESULTS: Of the 2.2 million Medigap insureds eligible for 
the study, 529,652 (24%) had osteoarthritis. Of these, 32,527 (6.1%) received a hip
or knee replacement surgery. Males were 6% (p  0.001) more likely than females to
have a replacement surgery. Patients residing in minority or lower-income neighbor-
hoods were less likely to receive a hip or knee replacement surgery. The surgery rate
decreased with age. Supplement plan type was not a strong predictor of the likelihood 
of hip or knee replacement. Disparities were much greater by comorbid condition and 
residential location. Obese patients were 1.79 (p  0.001) times as likely, whereas
patients with COPD were only 0.69 times (p  0.001) as likely to have a hip or knee 
replacement. Patients in rural areas were 14% (p  0.001) less likely than those in 
urban areas and patients residing in South Dakota, Idaho, and Alaska were 3.24
(p  0.001), 2.58 (p  0.001), and 2.49 (p  0.001) more likely than those in New
Jersey to have replacement surgery. CONCLUSIONS: Disparities in hip and knee
replacement surgery existed by age, gender, race, and income levels. Larger disparities 
were found by residential location and comorbid condition. AARP and UnitedHealth 
Group are designing interventions to address these disparities; these interventions will
begin in mid-2009.
